UPDATE 1-Home Capital sees 2nd-qtr loss on costs related to liquidity issue
June 29 Canadian lender Home Capital Group Inc said on Thursday it expects to record a loss in the second quarter due to costs related to its efforts to shore up liquidity.
March 28 Sanofi:
* Says U.S. list price of newly approved Dupixent atopic dermatitis drug $37,000 per patient per yearFurther company coverage: (Reporting by Ben Hirschler)
* Teck resources ltd - announced that its Mexican subsidiary has entered into a binding agreement with a subsidiary of Goldcorp Inc